Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT)

A novel biotin-DOTA conjugate (r-BHD: reduced biotinamidohexylamine-DOTA) was investigated in order to provide an efficient pretargeted antibody-guided radioimmunotherapy (PAGRIT) application. Preclinical and clinical results are described. (90)Y and (177)Lu were used to label r-BHD. The effect of p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of nuclear medicine and molecular imaging 2007-01, Vol.34 (1), p.68-77
Hauptverfasser:	Urbano, Nicoletta, Papi, Stefano, Ginanneschi, Mauro, De Santis, Rita, Pace, Silvia, Lindstedt, Ragnar, Ferrari, Liliana, Choi, Sunju, Paganelli, Giovanni, Chinol, Marco
Format:	Artikel
Sprache:	eng
Schlagworte:	Acids Animals Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Biotin - chemistry Biotin - pharmacokinetics Biotin - therapeutic use Cancer Clinical outcomes Drug Delivery Systems - methods Drug Evaluation, Preclinical Heterocyclic Compounds, 1-Ring - chemistry Heterocyclic Compounds, 1-Ring - pharmacokinetics Heterocyclic Compounds, 1-Ring - therapeutic use Isotope Labeling - methods Male Metabolic Clearance Rate Mice Mice, Inbred C57BL Monoclonal antibodies Organ Specificity Radiation therapy Radioimmunotherapy - methods Radioisotopes - chemistry Radioisotopes - pharmacokinetics Radioisotopes - therapeutic use Radiopharmaceuticals - chemical synthesis Radiopharmaceuticals - pharmacokinetics Radiopharmaceuticals - therapeutic use Tissue Distribution
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!